Table 4. Univariate and multivariate analyses of LRRFS.
| Variables | Median LRRFS, months (95% CI) | P-value | HR | P-value |
|---|---|---|---|---|
| Gender |
— |
0.75 |
— |
— |
| Male | 36 (0–74.41) | — | — | — |
| Female |
50 (39.07–60.92) |
— |
— |
— |
| Age |
— |
0.95 |
— |
— |
| ⩽60 years old | 36 (0–74.68) | — | — | — |
| >60 years old |
44 (36.16–51.84) |
— |
— |
— |
| pT stage of the primary tumour |
— |
<0.0001 |
— |
<0.0001 |
| pT1 | 96 (88.74–103.26) | — | 0.07 (0.02–0.27) | <0.0001 |
| pT2 | 60 (33.7–86.29) | — | — | 0.35 |
| pT3 | 50 (40.49–59.51) | — | — | 0.29 |
| pT4 |
12 (9.94–14.06) |
— |
— |
0.3 |
| pN of the primary tumour |
— |
0.001 |
— |
0.63 |
| pN0 | 50 (46.08–53.91) | — | — | — |
| pN+ |
12 (0–28.69) |
— |
— |
— |
| Thoracic nodal status |
— |
0.04 |
— |
— |
| pN0 | 51 (49.63–52.36) | — | — | — |
| pN+ |
15 (4.89–25.1) |
— |
— |
— |
| Neo-adjuvant chemotherapy before CRC |
— |
0.001 |
— |
0.8 |
| Yes | 12 (0–31.94) | — | — | — |
| No |
50 (46.12–53.88) |
— |
— |
— |
| Adjuvant chemotherapy after CRC |
— |
<0.0001 |
— |
0.64 |
| Yes | 12 (7.51–16.49) | — | — | — |
| No |
55 (48.9–61.1) |
— |
— |
— |
| Disease-free survival |
— |
0.31 |
— |
— |
| <24 months | 41 (7.5–74.5) | — | — | — |
| ⩾24 months |
49 (35.31–62.68) |
— |
— |
— |
| Number of thoracic metastases |
— |
0.003 |
— |
0.09 |
| 1 | 52 (46.85–57.14) | — | — | — |
| >1 |
15 (1.99–28) |
— |
— |
— |
| Liver metastases |
— |
0.02 |
— |
0.17 |
| Yes | 10 (4.62–15.38) | — | — | — |
| No |
50 (42.89–57.11) |
— |
— |
— |
| Neo-adjuvant chemotherapya |
— |
0.2 |
— |
0.19 |
| Yes | 30 (4.59–55.41) | — | — | — |
| No |
51 (47.04–54.96) |
— |
— |
— |
| Adjuvant chemotherapya |
— |
0.05 |
— |
0.89 |
| Yes | 51 (49.43–52.56) | — | — | — |
| No |
17 (4.88–29.11) |
— |
— |
— |
| Preoperative CEA |
— |
0.22 |
— |
— |
| <5 | 50 (39.96–64.04) | — | — | — |
| ⩾5 |
41 (12.15–69.85) |
— |
— |
— |
| Mutational status |
— |
<0.0001 |
— |
<0.0001 |
| WT | 72 (64.21–79.79) | — | — | — |
| mKRAS | 31 (14.48–47.52) | — | 0.16 (0.07–0.33) | <0.0001 |
| mBRAF | 4 (1.87–6.13) | — | 0.04 (0.02–0.11) | <0.0001 |
Abbreviations: CI=confidence interval; CRC=colorectal cancer; HR=hazard ratio; LRRFS=locoregional recurrence-free survival; mBRAF=mutant BRAF; mKRAS=mutant KRAS; CEA=carcinoembryonic antigen; WT=wild type. Bold values indicate significant P-values.
a
Neo-adjuvant and adjuvant chemotherapy were administered before and after thoracic metastasectomy. Given that the correlation between mutational status and pN status were correlated, mutational status was exclusively included in multivariate analyses.